There is room for all three companies in the hereditary transthyretin-mediated amyloidosis (hATTR) space – Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc. and Pfizer Inc. – to collectively grow the market rather than duking it out with each other for share in this rare disease setting, Alnylam CEO John Maraganore believes.
During the Biotechnology Innovation Organization’s annual meeting in Philadelphia, Maraganore talked to Scrip about how he sees competition playing out in the US hATTR market, where the majority of patients are undiagnosed, now that